Funding for this research was provided by:
Health Technology Assessment Programme (17/69/02)
Received: 15 January 2022
Accepted: 12 July 2022
First Online: 31 August 2022
Change Date: 20 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12916-022-02611-x
: Not applicable as this is a synthesis of existing literature.
: Not applicable as this is drawing on previously published data that we appropriately reference in the paper.
: KM is a member of the HTA PCCPI Panel (2018), HTA Prioritisation Committee A (Out of hospital) (2018–2023), HTA Prioritisation Committee A Methods Group (2018) and HTA Programme Oversight Committee (2018–2021). GW is a member of HTA PCCPI Panel (2015–2018), Pharmaceuticals Panel (2011–2015), HTA Prioritisation Committee A (Out of hospital) (2015–2021) and HTA Prioritisation Committee A Methods Group. DL is a member of the HTA Clinical Evaluation and Trials Committee (2016–2021). RH has delivered educational workshops on health economics, medicines management and HTA for cancer specialists supported by unrestricted sponsorship by the pharmaceutical industry and an industry association (March 2019). RH has not received fees personally, and these activities are not specific to the topic of this research.